📄 Extracted Text (470 words)
From: [email protected]
Sent: Thursday, December 13, 2012 11:01 PM
To: [email protected]
Subject: Hi Jeffrey
Attachments: Hall-Kapt genetics 2012.pdf; FINAL MD paper 11.27.12.pdf
I hope this email finds you well. I thought I'd send a quick update on our work.
But first an invitation: I think I mentioned that the Robert Wood Johnson Foundation has given us an education grant to
expand the dialogue and forge new collaborations in placebo studies. Our plan is to hold a series of symposia that will
bring together international experts in various fields and move toward multi-disciplinary models. The first in the series,
scheduled for next June 19 and 20, will address "The Science of Placebo" and involves the world's leading experts on
placebo: Fabrizio Benedetti (Turin, Italy), Predrag Petrovic (Karolinska Institute, Sweden), Tor Wager (Colorado) and
myself. In the last years, they've published all the breakthrough articles in such journals as Science, Neuron, Brain, New
England Journal and Lancet, especially elucidating the neurobiology of placebo effects. In addition to these public talks,
there will be an invitation-only seminar on the topic "What don't we know about the placebo effect?" I wanted to let
you know that you will receive a formal invitation to attend these and all related events. The remainder of the series
will take place over the subsequent two years.
Our first genetic finding on placebo responses was published last month. (I think I sent you the unpublished manuscript
before, but I'm now attaching the pdf) Following up on it, we obtained the data on a major cardiovascular prevention
trial and it appears to supports the genetic association with response to placebo. Once we and others figure out in what
situations this association holds, we believe it could have significant implications. Also, Molecular Psychiatry (the
highest impact psychiatry journal) has just accepted our first study neuroimaging the physician's brain while treating
patients. The results showed that they activate their own brain regions that has to do with expectancy of pain relief. I've
attached the still unpublished manuscript for you information. We're hoping to expand this model in a series of
innovative experiments where we monitor the brain and autonomic information simultaneous between physician and
patient.
Also, last month, I visited the FDA and met with the director of the Center for Drug Evaluation and Research (Janet
Woodcock) and her team. They want our Harvard program to team up with them and with the pharmaceutical industry
to create a non-profit consortium that would further explore placebo effects as they pertain to drug development. I'm
still deciding whether this option makes scientific sense. But it may be a win-win.
Finally, I wanted to say that we're still looking for partnerships and collaborations with independent foundations and
philanthropists. If your interests align with ours, we hope you will keep us in mind.
Best,
EFTA_R1_02099331
EFTA02706181
ℹ️ Document Details
SHA-256
b3d0b42013848800a7a7327cd3270b1b47cce174da432e61f15b7f1c064bea99
Bates Number
EFTA02706181
Dataset
DataSet-11
Document Type
document
Pages
1
Comments 0